Trial Profile

A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Oct 2022 Results of post hoc pooled analysis from NCT01982240; NCT02122471, NCT02387359, NCT02493452; evaluating the potential impact of age on plecanatide efficacy in Chronic Idiopathic Constipation and IBS-C, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
24 Jan 2022 Results of pooled analysis from (NCT02122471 and NCT01982240) assessing efficacy and safety along with concomitant acid suppression therapy's effect published in the Clinical Therapeutics
27 Oct 2021 Results of a post-hoc analysis from two studies (NCT01982240, NCT02122471) presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com